Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Board Appointment

2 Feb 2009 11:01

RNS Number : 6266M
Plant Health Care PLC
02 February 2009
 



02 February 2009

Plant Health Care plc

("Plant Health Care" or "the Company")

NEW BOARD APPOINTMENT

Plant Health Care (AIM: PHC.L), a leading provider of natural products to the agriculture and landscape industries, announces that Dr. Dominik Koechlin was appointed to its Board as a non-executive director on 30 January 2009.

Dr. Koechlin, 50, a Swiss national, graduated from the University of Berne with a doctorate in law. He also has an MBA from INSEAD, Fontainebleau, France. Dr. Koechlin is currently a non-executive director of LGT Bank in Liechtenstein, and the following Swiss-listed companies: EGL AG, Swissmetal AG and Clariant AG.

Dr. Koechlin began his career working at Bank Sarasin in Basel from 1986 to 1988. He founded Ellipson AG in 1990, a business and management consultancy specialised in environmentally sound management and corporate financing. From 1996, he was a member of the executive committee of Telecom PTT and Swisscom AG.

During his time at Swisscom, the leading telecommunications provider in Switzerland, Dr. Koechlin was responsible for the redesign of the Swisscom business model, preparation for the IPO of Swisscom and development and communication of corporate strategy, as well as the international participations of Swisscom. Since 2001, Dr. Koechlin has worked as an independent board member and consultant for a number of listed and private businesses.

Dr. Albert Fischer, Non-executive Chairman of Plant Health Care commented:: "Dr. Koechlin has a great deal of experience in advising profitable, high-growth listed companies and will be a very strong addition to the Plant Health Care Board."

There is no other information that is required to be disclosed pursuant to Schedule 2 paragraph (g) of the AIM Rules, save as set out below:

Dominik Koechlin

Current Directorships

Past Directorships within last 5 years

LGT Bank in Liechtenstein Limited

Crucell NV

Elektrizitäts-Gesellschaft Laufenburg AG

Sustainable Asset Management AG

Swissmetal AG

Berna Biotech AG

Clariant AG

Novavox AG

Avaloq AG

Hesperion AG

M2 AG

Corris AG

- ends -

For further information:

John Brady

Evolution Securities Limited

Tavistock Communications

Chief Executive

Tim Worlledge/Tim Redfern

Jeremy Carey/Simon Compton

Tel: 001 603 525 3702

Tel: 020 7071 4300

Tel: 020 7920 3150

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAILFEIFAIFIIA
Date   Source Headline
27th Jan 20214:41 pmRNSSecond Price Monitoring Extn
27th Jan 20214:36 pmRNSPrice Monitoring Extension
25th Jan 20217:00 amRNSTrading Statement
11th Jan 20217:00 amRNSNotice of Trading Statement/Investor Presentation
5th Jan 20213:37 pmRNSBrazil approves PHC279 to Control Soybean Rust
11th Dec 20207:00 amRNSInvestor Presentation
9th Nov 20207:00 amRNSPlant Health Care and Wilbur-Ellis sign Agreement
7th Oct 20207:00 amRNSGrant of Options
6th Oct 20207:00 amRNSNew US PREtec Patents Issued
2nd Oct 20205:48 pmRNSSignificant Shareholder
25th Sep 20207:00 amRNSInvestor Presentation
23rd Sep 20207:00 amRNSInvestor Presentation
15th Sep 20207:00 amRNSInterim Report 30 June 2020
29th Jul 20207:00 amRNSTrading Statement
26th Jun 20204:41 pmRNSSecond Price Monitoring Extn
26th Jun 20204:36 pmRNSPrice Monitoring Extension
25th Jun 20207:00 amRNSGrant of Options
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension
16th Jun 20207:00 amRNSPHC398 Approved by US EPA: PHC279 submitted to EPA
9th Jun 20207:00 amRNSGrant of options
2nd Jun 202011:13 amRNSResult of AGM
29th May 20207:00 amRNSHolding(s) in Company
27th May 20207:00 amRNSUpdate on PHC279 2019 Field Trials
6th May 20205:12 pmRNSAnnual Report & Accounts and AGM Notice Published
1st May 20203:21 pmRNSDirector/PDMR Shareholding
24th Apr 20207:00 amRNSResults for the year ended 31 December 2019
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20203:45 pmRNSHolding(s) in Company
19th Mar 20203:09 pmRNSHolding(s) in Company
16th Mar 202011:53 amRNSResults of General Meeting
11th Mar 20207:00 amRNSPHC279 Submitted for Regulatory Approval in Brazil
24th Feb 20209:18 amRNSResults of Placing and Subscription
24th Feb 20207:00 amRNSProposed Placing and Subscription
19th Feb 20207:00 amRNSBlock listing Interim Review
5th Feb 20207:00 amRNSEmploy California Registration
23rd Jan 20207:00 amRNSFirst US patent issues for PREtec peptide products
9th Jan 20207:00 amRNSBrazil Update
20th Dec 20197:00 amRNSHolding(s) in Company
19th Dec 20197:00 amRNSTrading Update
3rd Dec 20196:35 pmRNSHolding(s) in Company
22nd Nov 20192:11 pmRNSHolding(s) in Company
15th Nov 20193:42 pmRNSHolding(s) in Company
15th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSHolding(s) in Company
13th Nov 20194:40 pmRNSHolding(s) in Company
13th Nov 20194:08 pmRNSHolding(s) in Company
13th Nov 20193:59 pmRNSHolding(s) in Company
13th Nov 20193:42 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.